Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066611 | 0.90 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1060752 | 0.81 | MAPK13 (0.36) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL10203432 | 0.81 | MAPK13 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1062125 | 0.80 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065592 | 0.80 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3529339 | 0.78 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5116797 | 0.77 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065140 | 0.77 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065794 | 0.76 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5105130 | 0.76 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110009625-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-7759486-B2 | Substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090105478-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-7323472-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105478-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK13 43/4885MAPK12 85/4885 |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | MAPKAPK2, MAPK8, CREBBP | MAPK14 56/4885MAPK13 80/4885MAPK12 90/4885 |
| US-20110009625-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK13 43/4885MAPK12 85/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | MAPK14 22/4885MAPK13 25/4885MAPK12 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.